Lung resection for metastatic osteogenic sarcoma.
Osteogenic sarcoma, excluding the paraosteal osteosarcoma, has a grave prognosis, half of the patients dying within 1 year following ablative surgery of the primary lesion. Once pulmonary metastasis is detected, most patients do not survive more than 3 years. Various attempts by investigators to prolong patient survival, including surgery, chemotherapy, immunotherapy, radiation therapy, and combined modalities, have met with some success. This report is a summary of 13 patients who underwent lung resections and received adjuvant chemo- and/or immunotherapy for metastatic osteogenic sarcoma in our intstitute in the past 7 years.
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008175:Lung Neoplasms / Q000601:surgery* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000601:surgery; D012516:Osteosarcoma / Q000601:surgery* / Q000628:therapy; D011379:Prognosis; D012075:Remission, Spontaneous; D013997:Time Factors
D000970:Antineoplastic Agents